Expert Talk

Leadership Insights: 6thAnnual Rare & Genetic Kidney Disease Drug Development Summit

The most important shift I have seen is the move from phenotypefirst to genotypefirst thinking and that is changing everything from diagnosis to trial design Genetic testing is moving earlier in the workup particularly

Pharmacovigilance in the GLP-1 Era: Safety Surveillance Challenges for Obesity Medicines and Real-World Use

The rapid uptake of GLP therapies is pushing pharmacovigilance beyond traditional slower models built for smaller and more controlled treatment populations Obesity use is broader longerterm

From Clinical Trials to Pharmacovigilance: A Multi-Agent Future

The industry has automated within silos not across them Your clinical data management systems dont communicate with safety databases Trial monitoring operates independently from postmarket surveillance

The Quiet Disciplines of High-Performance Labs: Talent, Modalities, and the Data-Native Future

In smallmolecule work a competent team can be built by hiring for HPLC method validation and impurity characterisation The playbook is established the regulatory pathway familiar and most midcareer scientists can slot in and deliver

Building the Bridge: How B2B Media Is Shaping the Future of Chemical Engineering

The shift is already well underway BB medias value used to be measured in reach how many engineers received your magazine how many clicks your digital content generated What downstream companies

GLP-1 Therapies in Real-World Weight Care: Provider Insights on Adoption, Adherence, and Outcomes

Before GLPs obesity management was neglected There was no real plan or employer focus on obesity GLPs have completely changed that For good and bad never has a drug been demanded by consumers like this The good thing is that there now is a focus on obesity and the upside of treating it properly in terms of improved cardiometabolic outcomes